Business
Final Results for the year ended 30 April 2019
Final Results for the year ended 30 April 2019.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5500J Scancell Holdings Plc 20 August 2019 \n\n 20 August 2019\n \n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nFinal Results for the year ended 30 April 2019\n \nImmunotherapy pipeline advances; new investment provides further endorsement of future potential\n \nScancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces its results for the year ended 30 April 2019. \n \nHighlights:\n \n· The Company received regulatory and ethical approval for the UK arm of the SCIB1 Phase 2 clinical trial\n \n· Scancell exercised its option to a worldwide commercial licence for the use of Ichor Medical Systems' TriGrid® 2.0 electroporation delivery system with SCIB1\n \n· Patents granted in Europe and Japan providing broad protection of Scancell's Moditope® technology; a patent granted in the US that provides protection for Modi-1; and a further European patent granted relating to FG88, a monoclonal antibody directed against tumour associated glycans\n \n· Strategic research collaboration with the Rheumatology Unit at the Karolinska Institute expanded to explore the potential of Moditope® to develop multiple immunotherapeutic agents for a range of different cancers\n \n· Pre-clinical development underway with Modi-2, including progress made in the characterisation of homocitrullinated peptides allowing Modi-2 to potentially address tumours with a particularly immunosuppressive environment\n \n· Dr Samantha Paston appointed as Head of Research and Dr Adrian Parry appointed as Head of Manufacturing\n \n· Professor Lindy Durrant received the Waldenström award from the Swedish Society of Oncology\n \n· £1.1m raised in an open offer to shareholders, following a placing of £6.9m at the end of the previous financial year\n \n· Loss for the 12-month period of £5.63 million (2018: loss: £4.19 million)\n \n· Group cash balance at 30 April 2019 was...